

Wetenschappelijke publicaties hart- en vaatziekten

Schwartz GG et al. (2018).

[Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.](#)

N. Engl. J. Med.; 379(22):2097-2107.

Armstrong PW et al. (2018).

[A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.](#)

JACC Heart Fail.; 6(2):96-104.

Claeys MJ et al. (2017).

[Real world insights on the initiation and treatment duration of oral antiplatelets in acute coronary syndromes: a retrospective cohort study.](#)

Eur. Heart J. Cardiovasc. Pharmacother.; 3(4):189-197.

Pieske B et al. (2017).

[Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOLuble guanylate Cyclase stimuloR in heArT failurE patientS with PRESERVED EF \(SOCRATES-PRESERVED\) study.](#)

Eur. Heart J.; 38(15):1119-1127.

Ridker PM et al. (2017).

[Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.](#)

N Engl J Med. 2017 Sep 21;377(12):1119-1131

Vardeny O et al. (2016).

[Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial.](#)

Eur. J. Heart Fail.; 18(10):1228-1234.

Teerlink JR et al. (2016).

[Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure \(COSMIC-HF\): a phase 2, pharmacokinetic, randomised, placebo-controlled trial.](#)

Lancet; 388(10062):2895-2903.

Teerlink JR et al. (2016).

[Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study.](#)

J. Am. Coll. Cardiol.; 67(12):1444-14557.

Gheorghiade M et al. (2015).

[Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.](#)

JAMA; 314(21):2251-62.

McMurray JJ et al. (2014).

[Angiotensin-neprilysin inhibition versus enalapril in heart failure.](#)

N Engl J Med. 2014 Sep 11;371(11):993-1004

Jessup M (2014).

[Neprilysin Inhibition – A Novel Therapy for Heart Failure.](#)

N. Engl. J. Med.; 371(11):1062-4.

Wetenschappelijke publicaties

Neurologie

G.J.D. Hengstman, J.L. De Bleecker, E. Feist, J. Vissing, C.P. Denton, M.N. Manoussakis, J.H. Slott, B.G.M. Van Engelen, F.H.J. van den Hoogen.

[Open-label trial of anti-TNF- \$\alpha\$ in dermato- en polymyositis treated concomitantly with methotrexate.](#)

Eur Neurol 2008; 59:159-163.

L.B. Goldstein, P. Amarenco, M. Lamonte, S. Gilbert, M. Messig, A. Callahan, M. Hennerici, H. Sillesen, K.M. Welch; SPARCL Investigators.

[Relative effects of statin therapy on stroke and cardio-vascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels \(SPARCL\) Study.](#)

Stroke 2008; 39:2444-2448

S. Chaturvedi, J. Zivin, A. Breazna, P. Amarenco, A. Callahan, L.B. Goldstein, M. Hennerici, H. Sillesen, A. Rudolph, M.A. Welch; SPARCL Investigators.

[Effect of atorvastatin in elderly patients with recent stroke or transient ischemic attack.](#)

Neurology 2009; 72:688-694

J-M. Léger, J.L. De Bleecker, C. Sommer, W. Robbrecht, M. Saarela, J. kamienowski, Z. Stelmasiak, O. Mielke, B. Tackenberg, A. Shebi, A. Bauhofer, O. Zenker, I.S.J. Merkies, PRIMA study investigators.

[Efficacy and safety of privergin in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study.](#)

J Periph Nerv Syst, 2013;18:130-140

M.E. Cudkowicz, L.H. van den Berg, J.M. Shefner, H. Mitsumoto, J.S. Mora, A. Ludolph, O. Hardiman, M.E. Bozik, E.W. Ingersoll, D. Archibald, A.L. Meyers, Y. Dong, W.R. Farwell, D.A. Kerr, EMPOWER Investigators.

[Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis \(EMPOWER\): a randomized, double-blind, phase 3 trial.](#)

Lancet Neurol 2013; 12:1059-1067

Gang Q, Bettencourt C, Machado PM, Fox Z, Brady S, Healy E, Parton M, Holton JL, Hilton-Jones D, Shieh PB, Zanolini E, De Paepe B, De Bleecker J, Shaibani A, Ripolone M, Violano R, Moggio M, Barohn RJ, Dimachkie MM, Mora M, Mantegazza R, Zanotti S, Hanna MG, Houlden H, Muscle Study Group, International IBM Genetics Consortium.

[The effects of an intronic polymorphism in TOMM40 and APOE genotypes in sporadic inclusion body myositis.](#)

Neurobiol Aging 2015;36(4):1766e1-3

Lilleker JB, Vencovsky J, Wang G, Wedderburn LR, Diederichsen LP, Schmidt J, Jordan P, Benveniste O, Danieli MG, Dankó K, Thuy NTP, Vázquez-Del Mercado M, Andersson H, De Paepe B, De Bleecker J, Maurer B, Pipitone N, McHugh N, Betteridge Z, New P, Cooper RG, Ollier WE, Lamb JA, Steen Krogh N, Lundberg IE, Hector Chinoy H, and EuroMyositis contributors.

[The EuroMyositis Registry: An International Collaborative Tool to Facilitate Myositis Research.](#)

Annals of the Rheumatic Diseases 2018, 77(1):30-39

Wetenschappelijke publicaties oncologie

Fontaine C et al. (2019).

[Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology \(BSMO\).](#)

Breast Cancer Research and Treatment; Epub ahead of print.

Tournoy K et al. (2018).

[Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals.](#)

Lung Cancer; 115:49-55.

Marth C et al. (2017).

[ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.](#)

Eur J Cancer.; 70:111-121.

Kaufman PA et al. (2015).

[Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane.](#)

J. Clin. Oncol.; 33(6):594-601.

Du Bois A et al. (2014).

[Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer.](#)

J. Clin. Oncol.; 32(30):3374-82.

Ryan CJ et al. (2013).

[Serum Androgens As Prognostic Biomarkers in Castration-Resistant Prostate Cancer: Results From an Analysis of a Randomized Phase III Trial.](#)

J. Clin. Oncol.; 31(22):2791-8.

Schmoll HJ et al. (2012).

[Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study \(HORIZON III\).](#)

J. Clin. Oncol.; 30(29):3588-95.

Scher HI et al. (2012).

[Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy.](#)

N. Engl. J. Med.; 367(13):1187-97.

Chinot OL et al. (2011).

[AVAglio: Phase 3 Trial of Bevacizumab Plus Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma Multiforme.](#)

Adv. Ther; 28(4):334-40.

Van Cutsem E et al. (2011).

[Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status.](#)

J. Clin. Oncol.; 29(15):2011-9.

de Bono JS et al. (2011).

[Abiraterone and Increased Survival in Metastatic Prostate Cancer.](#)

N. Engl. J. Med.; 364(21):1995-2005.

Sutherland S et al. (2010).

[Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience.](#)

Br. J. Cancer; 102(6):995-1002.

Stopeck AT et al. (2010).

[Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study.](#)

J. Clin. Oncol.; 28(35):5132-9.

Reed S et al. (2009).

[Cost Effectiveness of Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment.](#)

J. Clin. Oncol.; 27(13):2185-91.

Neyns B et al. (2009).

[Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma.](#)

Ann. Oncol.; 20(9):1596-603.